TNT (Treating to New Targets) Trial

18 Mar, 14

Aim

To investigate whether intensive statin therapy is associated with better outcomes than moderate statin therapy in patients with stable CHD

Study Patients

CHD patients with LDL <130 mg/dl

Study Group

Atorvastatin 80 mg (N=4995) vs. atorvastatin 10 mg (N=5006)

Study Period

4.9 years

Results

Significant reduction in major CV events with 80 mg atorvastatin

Significant reduction in key individual primary outcomes

Substantial benefits seen even in secondary end-points

Significantly lower LDL with 80 mg atorvastatin

Safety

Similar incidence of rhabdomyolysis in both groups (2 with 80 mg vs. 3 with 10 mg)
Significantly greater incidence of increased liver transaminases in patients receiving 80 mg atorvastatin (1.2% vs. 0.2% for 10 mg)
No significant increase in adverse effects in patients with LDL <70 mg/dl vs. those with higher LDL

Conclusion

Intensive lipid-lowering therapy with 80 mg atorvastatin in patients with stable CHD provides significant clinical benefit beyond that afforded by atorvastatin 10.

N Engl J Med 2005;352:1425-35

Related Topics